Cargando…

Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution

BACKGROUND: Although balloon-occluded retrograde transvenous obliteration (BRTO) is often selected to treat gastric varices caused by portal hypertension, data comparing BRTO and splenectomy with gastric devascularization (Sp + Dev) are limited. METHODS: From January 2009 to February 2018, 100 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshita, Ko, Ohira, Masahiro, Honmyo, Naruhiko, Kobayashi, Tsuyoshi, Murakami, Eisuke, Aikata, Hiroshi, Baba, Yasutaka, Kawano, Reo, Awai, Kazuo, Chayama, Kazuaki, Ohdan, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289714/
https://www.ncbi.nlm.nih.gov/pubmed/32533300
http://dx.doi.org/10.1007/s00535-020-01693-9
_version_ 1783545512911175680
author Oshita, Ko
Ohira, Masahiro
Honmyo, Naruhiko
Kobayashi, Tsuyoshi
Murakami, Eisuke
Aikata, Hiroshi
Baba, Yasutaka
Kawano, Reo
Awai, Kazuo
Chayama, Kazuaki
Ohdan, Hideki
author_facet Oshita, Ko
Ohira, Masahiro
Honmyo, Naruhiko
Kobayashi, Tsuyoshi
Murakami, Eisuke
Aikata, Hiroshi
Baba, Yasutaka
Kawano, Reo
Awai, Kazuo
Chayama, Kazuaki
Ohdan, Hideki
author_sort Oshita, Ko
collection PubMed
description BACKGROUND: Although balloon-occluded retrograde transvenous obliteration (BRTO) is often selected to treat gastric varices caused by portal hypertension, data comparing BRTO and splenectomy with gastric devascularization (Sp + Dev) are limited. METHODS: From January 2009 to February 2018, 100 patients with gastric varices caused by portal hypertension who underwent Sp + Dev (n = 45) or BRTO (n = 55) were included. Overall survival (OS) and the rebleeding rate were calculated using the inverse probability of a treatment weighting-adjusted log-rank test. Independent risk factors were identified by Cox regression analysis. Changes in liver function and adverse events after the procedures were analyzed. RESULTS: Patients in the Sp + Dev group tended to have lower platelet counts than those in the BRTO group, but liver function did not differ between these groups. The 5-year OS rates for the Sp + Dev and BRTO groups were 73.4 and 50.0% (p = 0.005), respectively. There were no significant differences in rebleeding rates between the two groups. Multivariate analysis showed that serum albumin level ≤3.6 g/dL, prothrombin time% activity (PT%) ≤80%, and serum creatinine level ≥0.84 mg/dL were poor prognostic factors. Although the Sp + Dev group had more short-term complications after procedures, Sp + Dev tended to be more effective in improving liver function than BRTO. CONCLUSIONS: Sp + Dev showed better OS and improvement of liver function compared with BRTO for the treatment of gastric varices caused by portal hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00535-020-01693-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7289714
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-72897142020-06-12 Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution Oshita, Ko Ohira, Masahiro Honmyo, Naruhiko Kobayashi, Tsuyoshi Murakami, Eisuke Aikata, Hiroshi Baba, Yasutaka Kawano, Reo Awai, Kazuo Chayama, Kazuaki Ohdan, Hideki J Gastroenterol Original Article—Liver, Pancreas, and Biliary Tract BACKGROUND: Although balloon-occluded retrograde transvenous obliteration (BRTO) is often selected to treat gastric varices caused by portal hypertension, data comparing BRTO and splenectomy with gastric devascularization (Sp + Dev) are limited. METHODS: From January 2009 to February 2018, 100 patients with gastric varices caused by portal hypertension who underwent Sp + Dev (n = 45) or BRTO (n = 55) were included. Overall survival (OS) and the rebleeding rate were calculated using the inverse probability of a treatment weighting-adjusted log-rank test. Independent risk factors were identified by Cox regression analysis. Changes in liver function and adverse events after the procedures were analyzed. RESULTS: Patients in the Sp + Dev group tended to have lower platelet counts than those in the BRTO group, but liver function did not differ between these groups. The 5-year OS rates for the Sp + Dev and BRTO groups were 73.4 and 50.0% (p = 0.005), respectively. There were no significant differences in rebleeding rates between the two groups. Multivariate analysis showed that serum albumin level ≤3.6 g/dL, prothrombin time% activity (PT%) ≤80%, and serum creatinine level ≥0.84 mg/dL were poor prognostic factors. Although the Sp + Dev group had more short-term complications after procedures, Sp + Dev tended to be more effective in improving liver function than BRTO. CONCLUSIONS: Sp + Dev showed better OS and improvement of liver function compared with BRTO for the treatment of gastric varices caused by portal hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00535-020-01693-9) contains supplementary material, which is available to authorized users. Springer Singapore 2020-06-12 2020 /pmc/articles/PMC7289714/ /pubmed/32533300 http://dx.doi.org/10.1007/s00535-020-01693-9 Text en © Japanese Society of Gastroenterology 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article—Liver, Pancreas, and Biliary Tract
Oshita, Ko
Ohira, Masahiro
Honmyo, Naruhiko
Kobayashi, Tsuyoshi
Murakami, Eisuke
Aikata, Hiroshi
Baba, Yasutaka
Kawano, Reo
Awai, Kazuo
Chayama, Kazuaki
Ohdan, Hideki
Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title_full Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title_fullStr Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title_full_unstemmed Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title_short Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
title_sort treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
topic Original Article—Liver, Pancreas, and Biliary Tract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289714/
https://www.ncbi.nlm.nih.gov/pubmed/32533300
http://dx.doi.org/10.1007/s00535-020-01693-9
work_keys_str_mv AT oshitako treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT ohiramasahiro treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT honmyonaruhiko treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT kobayashitsuyoshi treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT murakamieisuke treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT aikatahiroshi treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT babayasutaka treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT kawanoreo treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT awaikazuo treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT chayamakazuaki treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution
AT ohdanhideki treatmentoutcomesaftersplenectomywithgastricdevascularizationorballoonoccludedretrogradetransvenousobliterationforgastricvaricesapropensityscoreweightedanalysisfromasingleinstitution